Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinase-induced cell invasiveness.
BACKGROUND
The role of estrogens in the pathogenesis of lymphangioleiomyomatosis (LAM), an aggressive and destructive, eventually fatal lung disease of women, is poorly understood.


OBJECTIVE
The study was conducted to test the hypothesis that the lung disease in LAM is estrogen mediated and to determine whether estrogens contribute to the invasiveness of LAM.


METHODS
In vitro cell culture of spindle-shaped LAM cells (LAMD-SM) were isolated and propagated from affected lungs. Estrogen receptor (ER)-alpha and ERbeta analyses were conducted by RT-PCR. ERalpha and ERbeta, tissue inhibitor of metalloproteinase-2, and matrix metalloproteinases (MMP)-2 had Western blot analysis for protein assessment. Activity assays were performed for MT1-MMP, MMP-2, and tissue inhibitor of metalloproteinase-2. Assessment of MMP-2 promoter function was done via transfection assays. Cell invasion chambers were used to determine and quantitate cell invasiveness.


METHODS
The study was conducted at an academic medical center.


METHODS
Tissue and cells were obtained from patients as outlined in approved institution review board protocol (97/007).


METHODS
LAMD-SM cells were treated with a specific MMP-2 antibody or a nonspecific inhibitor, doxycycline.


METHODS
Activity of MMP-2 and invasiveness of LAMD-SM cells were measured.


RESULTS
LAMD-SM cells express functional ERs (ERalpha and ERbeta), which undergo rapid intracellular turnover in their unbound state. 17beta-estradiol (E(2)) enhances the transcriptional ER activity. E(2)-induced ER activation increases synthesis and activity of MMP-2 through posttranscriptional mechanisms in LAMD-SM. The E(2)/ER-mediated increase of MMP-2 promotes LAMD-SM invasiveness, in assays in vitro, which can be inhibited by specific antibodies against MMP-2 or doxycycline, an inhibitor of MMPs.


CONCLUSIONS
The invasion and destruction of lung parenchyma in LAM is, at least partially, an estrogen-MMP-driven process, which has major implications for therapeutic interventions.
Glassberg
Marilyn K
MK
Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Miami Miller School of Medicine, 1600 N.W. 10th Avenue, Miami, FL 33136, USA. mglassbe@med.miami.edu
Elliot
Sharon J
SJ
Fritz
Jason
J
Catanuto
Paola
P
Potier
Mylene
M
Donahue
Roger
R
Stetler-Stevenson
William
W
Karl
Michael
M
D002478:Cells, Cultured; D018450:Disease Progression; D004958:Estradiol / Q000494:pharmacology; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology / Q000209:etiology* / Q000473:pathology; D018192:Lymphangioleiomyomatosis / Q000201:enzymology / Q000209:etiology* / Q000473:pathology; D053511:Matrix Metalloproteinase 14 / Q000032:analysis; D020778:Matrix Metalloproteinase 2 / Q000502:physiology*; D009361:Neoplasm Invasiveness; D046988:Proteasome Endopeptidase Complex / Q000502:physiology; D012333:RNA, Messenger / Q000032:analysis; D011960:Receptors, Estrogen / Q000235:genetics / Q000502:physiology*; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000032:analysis; D014158:Transcription, Genetic
D012333:RNA, Messenger; D011960:Receptors, Estrogen; D019716:Tissue Inhibitor of Metalloproteinase-2; D004958:Estradiol; D020778:Matrix Metalloproteinase 2; D053511:Matrix Metalloproteinase 14; D046988:Proteasome Endopeptidase Complex